title: Intraocular pressure reduction and systemic absorption of timolol after administration of one side-coated inserts in rabbits.
abstract: The object of this study was to test whether flat, circular ophthalmic inserts releasing drug only from one side, would show improved activity parameters and reduced systemic absorption. To this purpose, uncoated and one-side coated hydroxypropylcellulose inserts containing timolol were prepared and evaluated. An acrylic copolymer (Eudragit RS) was used as coating material. Timolol release from inserts was studied both in vitro and in vivo. Timolol release in vitro from the coated inserts was much slower than from the uncoated ones, due to the smaller releasing surface area. Compared with timolol eyedrops (0.5%, 50 microliters), administration of 250 micrograms of timolol in uncoated or coated inserts produced a significantly greater hypotensive effect at 6 and 8 hr post instillation in rabbits with artificially increased intraocular pressure. The coated inserts containing 62.5 micrograms of timolol antagonised isoproterenol-induced ocular hypotension significantly more than timolol eyedrops (0.5%, 12.5 microliters) and uncoated inserts containing 62.5 micrograms of timolol. Both uncoated and coated inserts provided a significant sustaining of timolol release in tear fluid and decreased systemic peak concentrations of timolol with respect to the eyedrop control. However, one-side coated inserts failed to show significant improvements with respect to the uncoated samples.
authors: Laboratory of Pharmaceutical Technology/Biopharmaceutics, Institute of Pharmaceutical Chemistry, University of Pisa, Italy.
authors: M F
authors: MF
authors: Saettone
authors: P
authors: P
authors: Chetoni
authors: L
authors: L
authors: Cappanera
authors: U
authors: U
authors: Conte
authors: U
authors: U
authors: Finne
authors: K
authors: K
authors: Järvinen
authors: J
authors: J
authors: Salivirta
authors: A
authors: A
authors: Urtti
mesh_terms: D000042:Absorption; D000818:Animals; D001682:Biological Availability; D004337:Drug Carriers; D016503:Drug Delivery Systems; D007429:Intraocular Pressure / Q000187:drug effects*; D007545:Isoproterenol / Q000037:antagonists & inhibitors; D008297:Male; D015814:Ocular Hypotension / Q000139:chemically induced / Q000378:metabolism; D009883:Ophthalmic Solutions; D011817:Rabbits; D013666:Tears / Q000378:metabolism; D013999:Timolol / Q000008:administration & dosage* / Q000493:pharmacokinetics*
chemical_list: D004337:Drug Carriers; D009883:Ophthalmic Solutions; D013999:Timolol; D007545:Isoproterenol